Objective To evaluate the effects and safety of Tenapanor in hemodialysis patients with hyperphosphatemia by an updated meta-analysis. Methods All randomized controlled trials of Tenapanor were systematically searched in the Cochrane Library, PubMed, Embase, Web of Science, CNKI, Wan fang and VIP databases. The primary endpoint was the mean difference (MD) of serum phosphorus changes using Tenapanor versus placebo control, and the secondary endpoint was the rate difference (RD) of the target serum phosphorus level (serum phosphorus level: ≤6 mg/dl). A subgroup analysis was also conducted based on whether phosphate binders were used. Drug-related adverse reactions and diarrhea were collected to determine the safety of Tenapanor. Results There were 4 eligible trials that enrolled 677 patients. The studies showed that Tenapanor significantly reduced serum phosphorus level by 2.345mg/dl (95% CI:-2.798～-1.892; P＜0.001) and the achievement of the target serum phosphorus level (RD=0.363; 95% CI:0.147～0.579; P＜0.001) was better than placebo. However, drug-related adverse events (RD=0.461; 95% CI:0.284～0.637; P＜0.001), and diarrhea (RD=0.429; 95% CI:0.354～0.505; P＜0.001) were more serious than placebo. Subgroup analysis found that there were no significant differences in the magnitude of serum phosphorus level with (MD=-2.070; 95% CI:-2.885～-1.255; P＜0.001) or without (MD=-2.468; 95% CI:-3.013～-1.923; P＜0.001) phosphate binders. Conclusions The randomized placebo-controlled trials showed that Tenapanor significantly reduced serum phosphorus level in hemodialysis patients with hyperphosphatemia with or without use of phosphate binders. Diarrhea was present frequently but no serious drug-related adverse events occurred.
[1]Rastogi A, Bhatt N, Rossetti S, Beto J.Management of Hyperphosphatemia in End-Stage Renal Disease: A New Paradigm[J].J Ren Nutr, 2021, 31(1):21-34
[2]Kidney Disease: Improving Global Outcomes CKDMBDUWG.KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis,Evaluation,Prevention,and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)[J].Kidney Int Suppl, 2017, 7(1):1-59
[3]Cano-Megias M, Guisado-Vasco P, Bouarich H, et al.Coronary calcification as a predictor of cardiovascular mortality in advanced chronic kidney disease: a prospective long-term follow-up study[J].BMC Nephrol, 2019, 20(1):188-
[4]Cozzolino M, Ciceri P, Galassi A, et al.The Key Role of Phosphate on Vascular Calcification [J]. Toxins (Basel), 2019, 11(4).
[5]Cooper K, Quarles D, Kubo Y, et al.Relationship between reductions in parathyroid hormone and serum phosphorus during the management of secondary hyperparathyroidism with calcimimetics in hemodialysis patients[J].Nephron Clin Pract, 2012, 121(3-4):c124-30
[6]Bobeck EA, Meyer KM, Helvig C, et al.Sevelamer hydrochloride binds phosphate released from phytate in chicks fed 1alpha-hydroxy cholecalciferol[J].J Ren Nutr, 2013, 23(1):21-7
[7]Fissell RB, Karaboyas A, Bieber BA, et al.Phosphate binder pill burden,patient-reported non-adherence,and mineral bone disorder markers: Findings from the DOPPS[J].Hemodial Int, 2016, 20(1):38-49
[8]King AJ, Siegel M, He Y, et al.Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability [J]. Sci Transl Med, 2018, 10(456).
[9]Johansson S, Rosenbaum DP, Palm J, et al.Tenapanor administration and the activity of the H(+) -coupled transporter PepT1 in healthy volunteers[J].Br J Clin Pharmacol, 2017, 83(9):2008-14
[10].US FDA．therapeutic-biological-products/novel-drug-appro-vals-2019［EB/OL］．［2019-09-12］． https: / /www． fda． gov /drugs/new-drugs-fda-cders-new-molecular-entities-and-new．
[11]Melville NA.Medscape. FDA Rejects tenapanor for control of phosphorus in kidney disease. Accessed October 12, 2021.https://www.medscape.com/viewarticle/ 956066.
[12]Liberati A, Altman DG, Tetzlaff J, et al.The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration [J]. BMJ, 2009, 339: b2700.
[13]Higgins JP, Altman DG, Gotzsche PC, et al.The Cochrane Collaboration' s tool for assessing risk of bias in randomised trials [J]. BMJ, 2011, 343: d5928.
[14]Inaba M, Une Y, Ikejiri K, et al.Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan-A Phase 2 Randomized Trial[J].Kidney Int Rep, 2022, 7(2):177-88
[15]Shigematsu T, Une Y, Ikejiri K, et al.Therapeutic Effects of Add-On Tenapanor for Hemodialysis Patients with Refractory Hyperphosphatemia[J].Am J Nephrol, 2021, 52(6):496-506
[16]Pergola PE, Rosenbaum DP, Yang Y, et al.A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY)[J].J Am Soc Nephrol, 2021, 32(6):1465-73
[17]Block GA, Rosenbaum DP, Leonsson-Zachrisson M, et al.Effect of Tenapanor on Serum Phosphate in Patients Receiving Hemodialysis[J].J Am Soc Nephrol, 2017, 28(6):1933-42
[18]Shang D, Xie Q, Ge X, et al.Hyperphosphatemia as an independent risk factor for coronary artery calcification progression in peritoneal dialysis patients [J]. BMC Nephrol, 2015, 16: 107.
[19]Airy M, Schold JD, Jolly SE, et al.Cause-Specific Mortality in Patients with Chronic Kidney Disease and Atrial Fibrillation[J].Am J Nephrol, 2018, 48(1):36-45
[20]Slinin Y, Foley RN, Collins AJ.Calcium,phosphorus,parathyroid hormone,and cardiovascular disease in hemodialysis patients: the USRDS waves 1,3,and 4 study[J].J Am Soc Nephrol, 2005, 16(6):1788-93
[21]Kestenbaum B, Sampson JN, Rudser KD, et al.Serum phosphate levels and mortality risk among people with chronic kidney disease[J].J Am Soc Nephrol, 2005, 16(2):520-8
[22]Ix JH, Katz R, Kestenbaum BR, et al.Fibroblast growth factor-23 and death,heart failure,and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study)[J].J Am Coll Cardiol, 2012, 60(3):200-7
[23]Almqvist EG, Bondeson AG, Bondeson L, et al.Cardiac dysfunction in mild primary hyperparathyroidism assessed by radionuclide angiography and echocardiography before and after parathyroidectomy[J].Surgery, 2002, 132(6):1126-32
[24]Shinaberger CS, Greenland S, Kopple JD, et al.Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease?[J].Am J Clin Nutr, 2008, 88(6):1511-8
[25].
[26]Navaneethan SD, Palmer SC, Craig JC, et al.Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials[J].Am J Kidney Dis, 2009, 54(4):619-37
[27]Karamanidou C, Clatworthy J, Weinman J, et al.A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease [J]. BMC Nephrol, 2008, 9: 2.
[28]Block GA, Rosenbaum DP, Yan A, et al.Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial[J].J Am Soc Nephrol, 2019, 30(4):641-52
[29]Tonelli M, Pannu N, Manns B.Oral phosphate binders in patients with kidney failure[J].N Engl J Med, 2010, 362(14):1312-24
